Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 2/20 | 0.62 |
| ▸ | CDK1 | P06493 | 1/20 | 0.62 |
| ▸ | SYK | P43405 | 13/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.51 |
| ▸ | CHUK | O15111 | 2/20 | 0.51 |
| ▸ | IKBKG | Q9Y6K9 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.48 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.48 |
| ▸ | CDK9 | P50750 | 1/20 | 0.48 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6070034 | 0.90 | MKNK1 (0.55) | CDK2CDK1SYKIKBKBCHUK | |
| SCHEMBL6070706 | 0.88 | CDK1 (0.51) | CDK2CDK1SYK | |
| SCHEMBL6070167 | 0.88 | SYK (0.51) | CDK2CDK1SYKJAK2 | |
| SCHEMBL6070155 | 0.85 | CAMK2D (0.61) | CDK2IKBKBCHUKIKBKGCCNT1 | |
| SCHEMBL6070419 | 0.83 | AURKA (0.52) | CDK2SYKIKBKBCHUKIKBKG | |
| SCHEMBL6070176 | 0.82 | IKBKB (0.54) | CDK2IKBKBCHUK | |
| SCHEMBL6070028 | 0.80 | SYK (0.46) | CDK2CDK1SYKIKBKBCHUK | |
| SCHEMBL3534358 | 0.80 | CDK2 (0.69) | CDK2CDK1SYKIKBKBCHUK | |
| SCHEMBL8314825 | 0.79 | MTOR (0.57) | CDK2CDK1IKBKBCHUKIKBKG | |
| SCHEMBL2848881 | 0.79 | CDK1 (0.61) | CDK2CDK1SYKIKBKBCHUK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | claimed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | claimed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | claimed |
| US-7109204-B2 | controlling signal transduction; anticancer agents, antitumor agents, atherosclerosis, vision defects, antidiabetic agents, antiinflammatory agents | MERCK & CO., INC. (US) | 2006-09-19 | — | — | US | disclosed |
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | MERCK SHARP & DOHME CORP. | 2004-11-25 | — | — | US | disclosed |
| WO-2003011837-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2003-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235875-A1 | drugs used for signal transduction modulation, and for prophylaxis of angiogenesis, cancers, tumors, atherosclerosis, vision disorders and inflammatory diseases in mammals | FLT4, KDR, FLT1 | CDK2 190/4885CDK1 237/4885SYK 188/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.